OVIOPEPTIDES
Research Use OnlyGet free bacteriostatic water added to your next order when you join the list.
SEMAGLUTIDE - Image 1

SEMAGLUTIDE

(23)
1
OVIO
PEPTIDES
Price
$90.00
99%+ Purity
3rd Party Tested
Fast Shipping
Discreet Package

Lab Results

Research brief

Semaglutide — Canada Research Brief

Last updated April 11, 2026

Semaglutide is a long-acting GLP-1 receptor agonist approved by Health Canada for type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy).

Key facts

Canonical nameSemaglutide
Alternate namesOzempic, Wegovy, Rybelsus, NN9535
Drug classGLP-1 receptor agonist
CAS number910463-68-2
Molecular formulaC187H291N45O59
Molecular weight4113.58 g/mol
Read full brief

Reconstitution Guide

Add bacteriostatic water to achieve your desired concentration:

1ml BAC water5.0mg/ml
2ml BAC water2.5mg/ml
2.5ml BAC water2.0mg/ml

Inject water slowly against vial wall. Swirl gently, do not shake.

About This Product

SEMAGLUTIDE Canada - Premium GLP-1 Research Peptide Semaglutide stands as one of the most extensively studied GLP-1 receptor agonists in modern peptide research. Originally developed for type 2 diabetes investigation, Semaglutide has become a focal point for researchers studying appetite regulation, metabolic health, and glucose homeostasis. THE SCIENCE BEHIND SEMAGLUTIDE As a glucagon-like peptide-1 analogue, Semaglutide mimics the naturally occurring incretin hormone GLP-1. Its modified amino acid sequence provides extended plasma half-life compared to native GLP-1, enabling once-weekly research protocols. The peptide binds to GLP-1 receptors in the pancreas, gastrointestinal tract, and central nervous system. WHY RESEARCHERS CHOOSE SEMAGLUTIDE Semaglutide's documented effects in peer...

Form

Lyophilized Powder

Quantity

5mg

Storage

-20°C

Share:

Customer Reviews (23)

Research brief

Semaglutide — Canada Research Brief

Mechanism

Semaglutide activates the GLP-1 receptor, a class B G-protein-coupled receptor expressed in pancreatic β-cells, gastric smooth muscle, and hypothalamic appetite circuits. Downstream effects include:

  • Glucose-dependent insulin secretion from pancreatic β-cells, which improves postprandial glycaemia without the hypoglycaemia risk of sulfonylureas.
  • Glucagon suppression from α-cells.
  • Delayed gastric emptying, which flattens postprandial glucose peaks and contributes to early satiety.
  • Central appetite suppression via GLP-1 receptor populations in the arcuate nucleus and area postrema.

The fatty-acid side chain on Lys26 binds reversibly to plasma albumin, which protects the peptide from DPP-4 cleavage and renal clearance and gives semaglutide its ~165-hour half-life — the basis for once-weekly dosing.

Clinical evidence

The most-cited dataset for semaglutide in weight management is the STEP programme — eight phase-3 trials published 2021–2023. STEP 1 (Wilding et al., NEJM 2021) reported a mean weight reduction of −14.9% at 68 weeks with once-weekly 2.4 mg subcutaneous dosing versus −2.4% for placebo, in adults with BMI ≥30 or ≥27 with comorbidity.

For cardiovascular safety, SUSTAIN-6 (Marso et al., NEJM 2016) demonstrated a 26% relative risk reduction in the primary MACE composite endpoint in adults with type 2 diabetes at elevated cardiovascular risk.

How Canadian researchers source semaglutide

Canadian labs sourcing research-grade semaglutide should verify three things on every vendor: (1) per-batch HPLC purity ≥98%, (2) mass spectrometry confirming the expected 4,113.58 g/mol mass, and (3) domestic Canadian shipping to avoid customs holds on international incretin peptide shipments.

Comparisons

Storage

Store lyophilised semaglutide at −20°C for long-term storage. Reconstituted peptide is stable refrigerated at 2–8°C for approximately 4 weeks. Avoid repeated freeze-thaw cycles. See our reconstitution guide for step-by-step handling.

Frequently asked questions

What is semaglutide?
Semaglutide is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist approved by Health Canada and the U.S. FDA for type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy). It is a 31-amino-acid peptide with a fatty-acid side chain that binds albumin, extending its half-life to roughly one week.
Is semaglutide approved in Canada?
Yes, as a prescription drug under the brands Ozempic, Rybelsus, and Wegovy. Research-grade semaglutide sold as a laboratory chemical is a separate, unapproved form that is for non-clinical laboratory research use only — it is not a substitute for a prescribed medication.
How does semaglutide differ from tirzepatide and retatrutide?
Semaglutide is a single GLP-1 receptor agonist. Tirzepatide is a dual GLP-1 / GIP co-agonist. Retatrutide is an investigational triple agonist adding glucagon receptor activity. In head-to-head clinical programmes, mean weight reduction ranks retatrutide > tirzepatide > semaglutide, although only semaglutide and tirzepatide are approved.
What is semaglutide's molecular weight?
Semaglutide has a molecular weight of 4,113.58 g/mol, a molecular formula of C187H291N45O59, and CAS number 910463-68-2. It is manufactured by solid-phase peptide synthesis with a C18 fatty-acid spacer attached to Lys26.

References

  1. [1]Wilding JPH, Batterham RL, Calanna S, et al.. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine, 2021. DOI: 10.1056/NEJMoa2032183
  2. [2]Marso SP, Bain SC, Consoli A, et al.. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine, 2016. DOI: 10.1056/NEJMoa1607141
  3. [3]National Center for Biotechnology Information. PubChem CID 56843331 — Semaglutide, 2024

Related research

Frequently Asked Questions

What is SEMAGLUTIDE used for in research?

SEMAGLUTIDE is a glp-1 receptor agonist primarily used for metabolic and diabetes research. Mimics glucagon-like peptide-1 to regulate blood sugar and appetite signaling. Researchers study SEMAGLUTIDE for its effects on weight management, type 2 diabetes, appetite control.

Can I buy SEMAGLUTIDE in Canada?

Yes, OVIOPEPTIDES ships SEMAGLUTIDE across all Canadian provinces including Ontario, British Columbia, Alberta, Quebec, Manitoba, Saskatchewan, and all territories. Our SEMAGLUTIDE is available for non-clinical laboratory research purposes only.

What purity is your SEMAGLUTIDE?

All SEMAGLUTIDE from OVIOPEPTIDES is verified at 99%+ purity through independent third-party HPLC testing. Every order includes a Certificate of Analysis confirming purity, molecular weight, and identity verification.

How should I store SEMAGLUTIDE?

Store lyophilized SEMAGLUTIDE powder at -20°C (freezer) in its original sealed vial. Once reconstituted with bacteriostatic water, refrigerate at 2-8°C and use within 4 weeks. Avoid repeated freeze-thaw cycles.

How do I reconstitute SEMAGLUTIDE?

To reconstitute SEMAGLUTIDE, inject bacteriostatic water slowly against the vial wall. Swirl gently - never shake. Common reconstitution volumes are 1ml, 2ml, or 2.5ml depending on desired concentration. Allow the powder to dissolve completely before use.

Is SEMAGLUTIDE legal in Canada?

SEMAGLUTIDE is legal to purchase in Canada for non-clinical laboratory research purposes. It is not approved by Health Canada for therapeutic use and is not intended for human consumption. OVIOPEPTIDES sells SEMAGLUTIDE strictly for research applications.

How does SEMAGLUTIDE compare to retatrutide?

SEMAGLUTIDE and retatrutide are both used in metabolic and diabetes research but have different mechanisms. SEMAGLUTIDE is a glp-1 receptor agonist, while retatrutide may work through different pathways. Researchers often study these peptides together for comparative analysis.

What documentation comes with SEMAGLUTIDE?

Every SEMAGLUTIDE order from OVIOPEPTIDES includes a Certificate of Analysis (COA) documenting: HPLC purity results (99%+), mass spectrometry data, batch number, manufacturing date, and expiration date. This ensures full traceability for your research.